Publication

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

IMPACT Study Collaborators, Page, E. C., Bancroft, E. K., Brook, M. N., Assel, M., Hassan Al Battat, M., Thomas, S., Taylor, N., Chamberlain, A., Pope, J., Raghallaigh, H. N., Evans, D. G., Rothwell, J., Maehle, L., Grindedal, E. M., James, P., Mascarenhas, L., McKinley, J., Side, L., Thomas, T., van Asperen, C., Vasen, H., Kiemeney, L. A., Ringelberg, J., Jensen, T. D., Osther, P. J. S., Helfand, B. T., Genova, E., Oldenburg, R. A., Cybulski, C., Wokolorczyk, D., Ong, K-R., Huber, C., Lam, J., Taylor, L., Salinas, M., Feliubadaló, L., Oosterwijk, J. C., van Zelst-Stams, W., Cook, J., Rosario, D. J., Domchek, S., Powers, J., Buys, S., O'Toole, K., Ausems, M. G. E. M., Schmutzler, R. K., Rhiem, K., Izatt, L., Tripathi, V. & Cardoso, M., Dec-2019, In : European Urology. 76, 6, p. 831-842 12 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

IMPACT Study Collaborators, Page, E. C., Bancroft, E. K., Brook, M. N., Assel, M., Hassan Al Battat, M., ... Cardoso, M. (2019). Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 76(6), 831-842. https://doi.org/10.1016/j.eururo.2019.08.019

Author

IMPACT Study Collaborators ; Page, Elizabeth C ; Bancroft, Elizabeth K ; Brook, Mark N ; Assel, Melissa ; Hassan Al Battat, Mona ; Thomas, Sarah ; Taylor, Natalie ; Chamberlain, Anthony ; Pope, Jennifer ; Raghallaigh, Holly Ni ; Evans, D Gareth ; Rothwell, Jeanette ; Maehle, Lovise ; Grindedal, Eli Marie ; James, Paul ; Mascarenhas, Lyon ; McKinley, Joanne ; Side, Lucy ; Thomas, Tessy ; van Asperen, Christi ; Vasen, Hans ; Kiemeney, Lambertus A ; Ringelberg, Janneke ; Jensen, Thomas Dyrsø ; Osther, Palle J S ; Helfand, Brian T ; Genova, Elena ; Oldenburg, Rogier A ; Cybulski, Cezary ; Wokolorczyk, Dominika ; Ong, Kai-Ren ; Huber, Camilla ; Lam, Jimmy ; Taylor, Louise ; Salinas, Monica ; Feliubadaló, Lidia ; Oosterwijk, Jan C ; van Zelst-Stams, Wendy ; Cook, Jackie ; Rosario, Derek J ; Domchek, Susan ; Powers, Jacquelyn ; Buys, Saundra ; O'Toole, Karen ; Ausems, Margreet G E M ; Schmutzler, Rita K ; Rhiem, Kerstin ; Izatt, Louise ; Tripathi, Vishakha ; Cardoso, Marta. / Interim Results from the IMPACT Study : Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. In: European Urology. 2019 ; Vol. 76, No. 6. pp. 831-842.

Harvard

IMPACT Study Collaborators, Page, EC, Bancroft, EK, Brook, MN, Assel, M, Hassan Al Battat, M, Thomas, S, Taylor, N, Chamberlain, A, Pope, J, Raghallaigh, HN, Evans, DG, Rothwell, J, Maehle, L, Grindedal, EM, James, P, Mascarenhas, L, McKinley, J, Side, L, Thomas, T, van Asperen, C, Vasen, H, Kiemeney, LA, Ringelberg, J, Jensen, TD, Osther, PJS, Helfand, BT, Genova, E, Oldenburg, RA, Cybulski, C, Wokolorczyk, D, Ong, K-R, Huber, C, Lam, J, Taylor, L, Salinas, M, Feliubadaló, L, Oosterwijk, JC, van Zelst-Stams, W, Cook, J, Rosario, DJ, Domchek, S, Powers, J, Buys, S, O'Toole, K, Ausems, MGEM, Schmutzler, RK, Rhiem, K, Izatt, L, Tripathi, V & Cardoso, M 2019, 'Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers', European Urology, vol. 76, no. 6, pp. 831-842. https://doi.org/10.1016/j.eururo.2019.08.019

Standard

Interim Results from the IMPACT Study : Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. / IMPACT Study Collaborators; Page, Elizabeth C; Bancroft, Elizabeth K; Brook, Mark N; Assel, Melissa; Hassan Al Battat, Mona; Thomas, Sarah; Taylor, Natalie; Chamberlain, Anthony; Pope, Jennifer; Raghallaigh, Holly Ni; Evans, D Gareth; Rothwell, Jeanette; Maehle, Lovise; Grindedal, Eli Marie; James, Paul; Mascarenhas, Lyon; McKinley, Joanne; Side, Lucy; Thomas, Tessy; van Asperen, Christi; Vasen, Hans; Kiemeney, Lambertus A; Ringelberg, Janneke; Jensen, Thomas Dyrsø; Osther, Palle J S; Helfand, Brian T; Genova, Elena; Oldenburg, Rogier A; Cybulski, Cezary; Wokolorczyk, Dominika; Ong, Kai-Ren; Huber, Camilla; Lam, Jimmy; Taylor, Louise; Salinas, Monica; Feliubadaló, Lidia; Oosterwijk, Jan C; van Zelst-Stams, Wendy; Cook, Jackie; Rosario, Derek J; Domchek, Susan; Powers, Jacquelyn; Buys, Saundra; O'Toole, Karen; Ausems, Margreet G E M; Schmutzler, Rita K; Rhiem, Kerstin; Izatt, Louise; Tripathi, Vishakha; Cardoso, Marta.

In: European Urology, Vol. 76, No. 6, 12.2019, p. 831-842.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

IMPACT Study Collaborators, Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M et al. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology. 2019 Dec;76(6):831-842. https://doi.org/10.1016/j.eururo.2019.08.019


BibTeX

@article{4e768f8d27aa4f87a55bcfa8294e624a,
title = "Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers",
abstract = "Background: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations.Objective: To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status.Design, setting, and participants: Men aged 40-69 yr with a germline pathogenic BRCA1/ 2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA> 3.0 ng/ml, men were offered prostate biopsy.Outcome measurements and statistical analysis: PSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians.Results and limitations: A total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73{\%} vs 60{\%}). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77{\%} vs 40{\%}; p= 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at biopsy than PSA alone (AUC = 0.65).Conclusions: After 3 yr of screening, compared with noncarriers, BRCA2 mutation carriers were associated with a higher incidence of PrCa, younger age of diagnosis, and clinically significant tumours. Therefore, systematic PSA screening is indicated for men with a BRCA2 mutation. Further follow-up is required to assess the role of screening in BRCA1 mutation carriers.Patient summary: We demonstrate that after 3 yr of prostate-specific antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than in those without these mutations. We recommend that male BRCA2 carriers are offered systematic PSA screening. (C) 2019 The Authors. Published by Elsevier B.V.",
keywords = "BRCA1, BRCA2, Prostate-specific-antigen, Prostate cancer, Targeted prostate screening, CANCER MORTALITY, BREAST, TRIAL, MEN, PREDICTION, SURVIVAL, INCREASE, OVARIAN, ERSPC",
author = "{IMPACT Study Collaborators} and Page, {Elizabeth C} and Bancroft, {Elizabeth K} and Brook, {Mark N} and Melissa Assel and {Hassan Al Battat}, Mona and Sarah Thomas and Natalie Taylor and Anthony Chamberlain and Jennifer Pope and Raghallaigh, {Holly Ni} and Evans, {D Gareth} and Jeanette Rothwell and Lovise Maehle and Grindedal, {Eli Marie} and Paul James and Lyon Mascarenhas and Joanne McKinley and Lucy Side and Tessy Thomas and {van Asperen}, Christi and Hans Vasen and Kiemeney, {Lambertus A} and Janneke Ringelberg and Jensen, {Thomas Dyrs{\o}} and Osther, {Palle J S} and Helfand, {Brian T} and Elena Genova and Oldenburg, {Rogier A} and Cezary Cybulski and Dominika Wokolorczyk and Kai-Ren Ong and Camilla Huber and Jimmy Lam and Louise Taylor and Monica Salinas and Lidia Feliubadal{\'o} and Oosterwijk, {Jan C} and {van Zelst-Stams}, Wendy and Jackie Cook and Rosario, {Derek J} and Susan Domchek and Jacquelyn Powers and Saundra Buys and Karen O'Toole and Ausems, {Margreet G E M} and Schmutzler, {Rita K} and Kerstin Rhiem and Louise Izatt and Vishakha Tripathi and Marta Cardoso",
note = "Copyright {\circledC} 2019 The Authors. Published by Elsevier B.V. All rights reserved.",
year = "2019",
month = "12",
doi = "10.1016/j.eururo.2019.08.019",
language = "English",
volume = "76",
pages = "831--842",
journal = "European Urology",
issn = "0302-2838",
publisher = "ELSEVIER SCIENCE BV",
number = "6",

}

RIS

TY - JOUR

T1 - Interim Results from the IMPACT Study

T2 - Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

AU - IMPACT Study Collaborators

AU - Page, Elizabeth C

AU - Bancroft, Elizabeth K

AU - Brook, Mark N

AU - Assel, Melissa

AU - Hassan Al Battat, Mona

AU - Thomas, Sarah

AU - Taylor, Natalie

AU - Chamberlain, Anthony

AU - Pope, Jennifer

AU - Raghallaigh, Holly Ni

AU - Evans, D Gareth

AU - Rothwell, Jeanette

AU - Maehle, Lovise

AU - Grindedal, Eli Marie

AU - James, Paul

AU - Mascarenhas, Lyon

AU - McKinley, Joanne

AU - Side, Lucy

AU - Thomas, Tessy

AU - van Asperen, Christi

AU - Vasen, Hans

AU - Kiemeney, Lambertus A

AU - Ringelberg, Janneke

AU - Jensen, Thomas Dyrsø

AU - Osther, Palle J S

AU - Helfand, Brian T

AU - Genova, Elena

AU - Oldenburg, Rogier A

AU - Cybulski, Cezary

AU - Wokolorczyk, Dominika

AU - Ong, Kai-Ren

AU - Huber, Camilla

AU - Lam, Jimmy

AU - Taylor, Louise

AU - Salinas, Monica

AU - Feliubadaló, Lidia

AU - Oosterwijk, Jan C

AU - van Zelst-Stams, Wendy

AU - Cook, Jackie

AU - Rosario, Derek J

AU - Domchek, Susan

AU - Powers, Jacquelyn

AU - Buys, Saundra

AU - O'Toole, Karen

AU - Ausems, Margreet G E M

AU - Schmutzler, Rita K

AU - Rhiem, Kerstin

AU - Izatt, Louise

AU - Tripathi, Vishakha

AU - Cardoso, Marta

N1 - Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

PY - 2019/12

Y1 - 2019/12

N2 - Background: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations.Objective: To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status.Design, setting, and participants: Men aged 40-69 yr with a germline pathogenic BRCA1/ 2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA> 3.0 ng/ml, men were offered prostate biopsy.Outcome measurements and statistical analysis: PSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians.Results and limitations: A total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p= 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at biopsy than PSA alone (AUC = 0.65).Conclusions: After 3 yr of screening, compared with noncarriers, BRCA2 mutation carriers were associated with a higher incidence of PrCa, younger age of diagnosis, and clinically significant tumours. Therefore, systematic PSA screening is indicated for men with a BRCA2 mutation. Further follow-up is required to assess the role of screening in BRCA1 mutation carriers.Patient summary: We demonstrate that after 3 yr of prostate-specific antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than in those without these mutations. We recommend that male BRCA2 carriers are offered systematic PSA screening. (C) 2019 The Authors. Published by Elsevier B.V.

AB - Background: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations.Objective: To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status.Design, setting, and participants: Men aged 40-69 yr with a germline pathogenic BRCA1/ 2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA> 3.0 ng/ml, men were offered prostate biopsy.Outcome measurements and statistical analysis: PSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians.Results and limitations: A total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p= 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at biopsy than PSA alone (AUC = 0.65).Conclusions: After 3 yr of screening, compared with noncarriers, BRCA2 mutation carriers were associated with a higher incidence of PrCa, younger age of diagnosis, and clinically significant tumours. Therefore, systematic PSA screening is indicated for men with a BRCA2 mutation. Further follow-up is required to assess the role of screening in BRCA1 mutation carriers.Patient summary: We demonstrate that after 3 yr of prostate-specific antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than in those without these mutations. We recommend that male BRCA2 carriers are offered systematic PSA screening. (C) 2019 The Authors. Published by Elsevier B.V.

KW - BRCA1

KW - BRCA2

KW - Prostate-specific-antigen

KW - Prostate cancer

KW - Targeted prostate screening

KW - CANCER MORTALITY

KW - BREAST

KW - TRIAL

KW - MEN

KW - PREDICTION

KW - SURVIVAL

KW - INCREASE

KW - OVARIAN

KW - ERSPC

U2 - 10.1016/j.eururo.2019.08.019

DO - 10.1016/j.eururo.2019.08.019

M3 - Article

VL - 76

SP - 831

EP - 842

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -

ID: 98457788